Cadrenal Therapeutics, Inc. - Common Stock — 재무제표 (NASDAQ:CVKD) | MetaTrader

전체 차트 열기 Full chart

뉴스

Cadrenal schedules FDA meeting for HIT drug CAD-1005

카데레날 테라퓨틱스, 2상 임상 결과 발표 후 주가 급등

Cadrenal Therapeutics stock surges on Phase 2 trial results

카드레날, HIT 임상시험서 CAD-1005 혈전 감소 효과 보여

Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial

카드레날, 혈액 질환 치료제 ’12-LOX 억제제’ 잠재력 강조

Cadrenal highlights potential of 12-LOX inhibitor for blood disorder

Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox

Cadrenal Therapeutics appoints PTC Therapeutics CMO to board

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc.

캐드레날 테라퓨틱스 CFO Szot, 주식 1496달러 상당 매도